Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Neogen total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Neogen's total debt was $1.55B at Aug 31, 2026. For fiscal 2026 it was $1.59B, up 78.2% from the year before. The highest annual figure on record is $1.79B in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $1.59B | +78.2% |
| FY2025 | May 31, 2025 | $894.10M | +0.4% |
| FY2024 | May 31, 2024 | $890.84M | -50.1% |
| FY2023 | May 31, 2023 | $1.79B | – |
| FY2022 | May 31, 2022 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $1.55B | -2.4% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $1.59B | +78.2% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $1.59B | +78.9% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $1.59B | +79.0% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $1.59B | +79.1% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $894.10M | +0.4% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $890.61M | +0.0% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $889.87M | +0.0% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $889.13M | +0.0% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $890.84M | -50.1% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $890.17M | +0.6% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $889.48M | -3.7% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $888.82M | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $1.79B | – |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $884.70M | – |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $923.96M | – |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $0 | – |
See a number that looks wrong?